JOHNSON & JOHNSON

Pharmaceutical Preparations·NEW BRUNSWICK, NJ·FY end 01/03·CIK 200406

CEO Pay Ratio

—

J. Duato

CEO Total Comp

$32.8M

J. Duato

Median Employee

$83,000

Revenue

$94.2B

FY 2025

Net Income

$26.8B

FY 2025

Free Cash Flow

$19.7B

FY 2025

Net Margin

28.5%

Insider Net (180d)

-$80.7M

0 buys / 19 sales

CEO Pay Accountability

CEO comp as % of net income

0.12%

For every $1,000 of profit, $1.22 flows to the CEO.

CEO comp as % of buybacks

0.55%

CEO comp equals 5.5‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$94.2B	$88.8B	$21.4B	$94.9B	$93.8B
Gross Profit	$63.9B	$61.4B	$14.6B	$63.9B	$63.9B
Operating Income	—	—	—	—	—	—
Net Income	$26.8B	$14.1B	$4.0B	$17.9B	$20.9B
Operating CF	$24.5B	$24.3B	$22.8B	$21.2B	$23.4B
Capex	$4.8B	$4.4B	$4.5B	$4.0B	$3.7B
Free Cash Flow	$19.7B	$19.8B	$18.2B	$17.2B	$19.8B
Buybacks	$6.0B	$2.4B	$5.1B	$6.0B	$3.5B
Dividends	—	—	—	—	—	—

Gross Margin	67.9%	69.1%	68.2%	67.3%	68.2%
Operating Margin	—	—	—	—	—	—
Net Margin	28.5%	15.8%	18.9%	18.9%	22.3%
FCF Margin	20.9%	22.3%	85.3%	18.1%	21.1%
R&D / Revenue	0.1%	2.1%	2.3%	—	—
Effective Tax	17.7%	15.7%	36.0%	17.4%	8.3%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	30.2%	12.3%	27.7%	35.1%	17.5%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
J. DuatoChairman/CEO	$1.6M	$15.0M	$5.9M	$4.3M	$5.9M	$32.8M
J. ReedEVP, Innovative Medicine, R&D	$1.2M	$2.4M	$1.8M	$6.6M	$12.3M	—
J. TaubertEVP, WWC Innovative Medicine	$1.2M	$2.4M	$2.0M	$8.3M	$14.1M	—
J. WolkEVP, CFO	$1.2M	$2.5M	$1.9M	$8.7M	$14.5M	—
T. SchmidEVP, WWC, MedTech	$942.3K	$1.3M	$1.5M	$5.4M	$9.4M	—